Literature DB >> 23689986

Development of an oxygen-sensitive degradable peptide probe for the imaging of hypoxia-inducible factor-1-active regions in tumors.

Masashi Ueda1, Kei Ogawa, Azusa Miyano, Masahiro Ono, Shinae Kizaka-Kondoh, Hideo Saji.   

Abstract

PURPOSE: We aimed to develop a radiolabeled peptide probe for the imaging of hypoxia-inducible factor-1 (HIF-1)-active tumors. PROCEDURES: We synthesized the peptide probes that contain or lack an essential sequence of the oxygen-dependent degradation of HIF-1α in proteasomes ((123/125)I-DKOP30 or (125)I-mDKOP, respectively). The degradation of probes was evaluated in vitro using cell lysates containing proteasomes. In vivo biodistribution study, planar imaging, autoradiography, and comparison between probe accumulation and HIF-1 transcriptional activity were also performed.
RESULTS: The (125)I-DKOP30 underwent degradation in a proteasome-dependent manner, while (125)I-mDKOP was not degraded. Biodistribution analysis showed (125)I-DKOP30 accumulation in tumors. The tumors were clearly visualized by in vivo imaging, and intratumoral distribution of (125)I-DKOP30 coincided with the HIF-1α-positive hypoxic regions. Tumoral accumulation of (125)I-DKOP30 was significantly correlated with HIF-1-dependent luciferase bioluminescence, while that of (125)I-mDKOP was not.
CONCLUSION: (123)I-DKOP30 is a useful peptide probe for the imaging of HIF-1-active tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689986     DOI: 10.1007/s11307-013-0647-6

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  32 in total

1.  HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia.

Authors:  D M Stroka; T Burkhardt; I Desbaillets; R H Wenger; D A Neil; C Bauer; M Gassmann; D Candinas
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

Review 2.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.

Authors:  Jean-Philippe Dales; Stéphane Garcia; Séverine Meunier-Carpentier; Lucile Andrac-Meyer; Olivier Haddad; Marie-Noölle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Int J Cancer       Date:  2005-09-20       Impact factor: 7.396

5.  PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative.

Authors:  Takashi Kudo; Masashi Ueda; Hiroaki Konishi; Hidekazu Kawashima; Yuji Kuge; Takahiro Mukai; Azusa Miyano; Shotaro Tanaka; Shinae Kizaka-Kondoh; Masahiro Hiraoka; Hideo Saji
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 6.  Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Authors:  Nadine Rohwer; Thorsten Cramer
Journal:  Drug Resist Updat       Date:  2011-04-03       Impact factor: 18.500

7.  Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients.

Authors:  Alexander W Eckert; Matthias H W Lautner; Andreas Schütze; Helge Taubert; Johannes Schubert; Udo Bilkenroth
Journal:  Histopathology       Date:  2011-03-25       Impact factor: 5.087

8.  Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.

Authors:  Takashi Kudo; Masashi Ueda; Yuji Kuge; Takahiro Mukai; Shotaro Tanaka; Maki Masutani; Yasushi Kiyono; Shinae Kizaka-Kondoh; Masahiro Hiraoka; Hideo Saji
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 9.  Oxygen, a source of life and stress.

Authors:  M Christiane Brahimi-Horn; Jacques Pouysségur
Journal:  FEBS Lett       Date:  2007-06-19       Impact factor: 4.124

10.  In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system.

Authors:  Takahiro Kuchimaru; Tetsuya Kadonosono; Shotaro Tanaka; Takashi Ushiki; Masahiro Hiraoka; Shinae Kizaka-Kondoh
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.240

View more
  3 in total

1.  Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression.

Authors:  Masashi Ueda; Hayato Hisada; Takashi Temma; Yoichi Shimizu; Hiroyuki Kimura; Masahiro Ono; Yuji Nakamoto; Kaori Togashi; Hideo Saji
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

Review 2.  Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.

Authors:  Circe D van der Heide; Simone U Dalm
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-05       Impact factor: 9.236

Review 3.  Radiolabeled probes targeting hypoxia-inducible factor-1-active tumor microenvironments.

Authors:  Masashi Ueda; Hideo Saji
Journal:  ScientificWorldJournal       Date:  2014-08-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.